Satsuma Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder f…

Biotechnology
US, South San Francisco [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

Satsuma Pharmaceuticals, Inc. has no acquisition track records yet.

M&A Deals · History

Satsuma Pharmaceuticals, Inc. has no acquisition track records yet.

End of STSA's Analysis
CIK: 1692830 CUSIP: 80405P107 ISIN: US80405P1075 LEI: - UEI: -
Secondary Listings
STSA has no secondary listings inside our databases.